Jovanny Zabaleta

Dr. Jovanny Zabaleta

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2012
Verified
Book Chapter
Closed access
PDF file
JZJovanny Zabaleta
Jovanny Zabaleta

4 October 2007 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
JZJovanny Zabaleta
Jovanny Zabaleta
HLHui-Yi Lin
Hui-Yi Lin
RSRosa A. Sierra
Rosa A. Sierra
MHM.Craig Hall
M.Craig Hall
PCPeter E. Clark
Peter E. Clark
AOAugusto C. Ochoa
Augusto C. Ochoa
Prostate cancer (CaP) is the second leading cause of cancer death in American men. Chronic inflammation has been one of several factors associated with the development of CaP. Single-nucleotide polymorphisms (SNPs) in cytokine genes have been associated with increased inflammation, increased cytokine production and possibly increased CaP risk. However, the effects of cytokine SNPs on CaP susceptibility have not been consistent. Using the genomic DNA collected in a CaP case–control study (557 cases and 547 controls), we pilot tested the interactions of nine functionally characterized SNPs of three cytokine genes in CaP risk using the multivariate adaptive regression splines (MARS)–logit models. African-Americans with the IL10−819TT genotype had a lower CaP risk [odds ratio (OR) = 0.27, 95% confidence interval (CI) = 0.07–1.01], but subjects with the genotype combination of IL1B−511CT/TT and IL10−592CC had a higher CaP risk (OR = 2.56, 95% CI = 1.09–6.02). In Caucasians, higher CaP risk was associated with the IL10−1082AG/GG genotype (OR = 3.62, 95% CI = 1.42–9.28), the genotype combination of IL10−1082AA plus IL1B−31TT/TC (OR = 2.92, 95% CI = 1.13–7.55) and the genotype combination of TNF−238GG plus IL10−592AA (OR = 2.14, 95% CI = 1.05–4.38). Our results highlight the importance of cytokine SNPs and their interactions in CaP risk.

6 July 2007 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
JZJovanny Zabaleta
Jovanny Zabaleta
BSBarbara G. Schneider
Barbara G. Schneider
KRKelli Ryckman
Kelli Ryckman
PHPleasant F. Hooper
Pleasant F. Hooper
MCM. Constanza Camargo
M. Constanza Camargo
AOAugusto C. Ochoa
Augusto C. Ochoa

16 April 2016 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
SSSilvia Juliana Serrano-Gomez
Silvia Juliana Serrano-Gomez
MSMaria Carolina Sanabria-Salas
Maria Carolina Sanabria-Salas
GHGustavo Hernández-Suarez
Gustavo Hernández-Suarez
OGOscar García
Oscar García
CSCamilo Silva
Camilo Silva
JZJovanny Zabaleta
Jovanny Zabaleta
Breast cancer is the most frequent malignancy in women worldwide. Distinct intrinsic subtypes of breast cancer have different prognoses, and their relative prevalence varies significantly among ethnic groups. Little is known about the prevalence of breast cancer intrinsic subtypes and their association with clinicopathological data and genetic ancestry in Latin Americans. Immunohistochemistry surrogates from the 2013 St. Gallen International Expert Consensus were used to classify breast cancers in 301 patients from Colombia into intrinsic subtypes. We analyzed the distribution of subtypes by clinicopathological variables. Genetic ancestry was estimated from a panel of 80 ancestry informative markers. Luminal B breast cancer subtype was the most prevalent in our population (37.2%) followed by luminal A (26.3%), non-basal triple negative (NBTN) (11.6%), basal like (9%), human epidermal growth factor receptor 2 (HER2) enriched (8.6%) and unknown (7.3%). We found statistical significant differences in distribution between Colombian region (P = 0.007), age at diagnosis (P = 0.0139), grade (P < 0.001) and recurrence (P < 0.001) according to intrinsic subtype. Patients diagnosed with HER2-enriched, basal-like and NBTN breast cancer had the highest African ancestry. Future studies analyzing the molecular profiles of breast cancer in Colombian women will help us understand the molecular basis of this subtype distribution and compare the molecular characteristics of the different intrinsic subtypes in Colombian patients.

27 May 2009 in Carcinogenesis
Verified
Journal Article
Closed access
JZJovanny Zabaleta
Jovanny Zabaleta
LSL. J. Su
L. J. Su
HLHui-Yi Lin
Hui-Yi Lin
RSR. A. Sierra
R. A. Sierra
MHM. C. Hall
M. C. Hall
AOA. C. Ochoa
A. C. Ochoa
Prostate cancer (PCa) is one of the most common cancers in the world. Inflammation has been described as a risk factor for PCa and depends on the production of cytokines in response to tissue damage or the presence of stimuli that induces cellular stress. Interindividual variation in cytokine production is partially controlled by single-nucleotide polymorphisms (SNPs) that have been associated with differential production of cytokines. We have recently showed that SNP-SNP interactions of cytokine genes are associated with PCa risk. However, little is known about the association of cytokine SNPs and PCa aggressiveness. In this study, we evaluated the association of 15 SNPs in five cytokine genes and aggressiveness of PCa in African- and Caucasian-American individuals. Caucasian Americans with the genotypes IL10-1082GG or IL1B+3954TT had 2.31-fold [95% confidence interval (CI) = 1.13-4.72] and 3.11 (95% CI = 1.20-8.06)-fold risk, respectively, of developing aggressive PCa, as compared with individuals without those genotypes. We did not find any associations in the African-American group. Using Multivariate Adaptive Regression Splines modeling for exploratory SNP-SNP interactions, our results showed that more aggressive PCa in Caucasians Americans is associated with the CT genotype at IL8-47 [odds ratios (OR) = 3.50; 95% CI = 1.13-10.88] or combined genotypes of IL1B-511CC and IL10-1082GG (OR = 3.38; 95% CI = 1.70-6.71). Unfortunately, the same analysis could not be performed in the African-Americans due to limited number of individuals. With limited sample size, the results from this study suggest that SNPs in cytokine genes may be associated with PCa aggressiveness. More extensive studies are warranted to validate our findings.

1 January 2012 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
JZJovanny Zabaleta
Jovanny Zabaleta
Helicobacter pylori (H. pylori) infection is a recognized risk factor for gastric cancer. The disease is one of the most common in the world and explains for a significant number of cancer cases and cancer-associated deaths worldwide. H. pylori infection induces huge array of responses at the gastric epithelial cells and the immune system, inducing both pro- and anti-inflammatory molecules that are intended to either perpetuate or control the infection. Despite the strong immune response, the infection is not cleared and can persist mostly without causing major significant discomfort in the human host. Among the mediators induced in response to the infection, microRNA (miRNA) have the potential to play a major impact on the outcome of the bacteria-host interaction. These miRNA are small 18–24 nucleotide long nucleotide molecules that can interact with mRNA molecules and block their translation into proteins or induce their degradation. Many efforts have been put into the generation of miRNA profiles and their role in gastric cancer. This has led to the identification of miRNA associated with promoting the inflammatory response initiated by the H. pylori infection, increasing the malignant progression of the gastric epithelium, and enhancing the invasiveness and migratory capacity of cancer cells. However, at the same time, several miRNA have been associated with events that are totally opposite, leading to reduced inflammation, inhibition of malignancy and increased apoptosis of transformed cells. In summary, as it is in many other examples, the role played by miRNA in gastric cancer is the results of a delicate balance between pro- and anti-cancer miRNA, and this balance is modified by the interaction of many players, many of which are still waiting to be discovered.